A number of domestic pharmaceutical companies are making efforts IDH inhibitors "competition race", cornerstone pharmaceutical industry first!

Pharmaceutical Network Industry Dynamics IDH inhibitors are well known and highly concerned in the field of anti-tumor drug research and development.
IDH inhibitors are currently being developed worldwide due to the huge demand for cancer treatment.
, Idhifa, an IDH2 inhibitor developed by Agios and Xinji, and Tibsovo, an oral mutant IDH1 inhibitor discovered and developed by Agios, have been approved for market.
addition, there are Novarma's IDH305, Bayer's BAY1436032 and Forma Therapeutics' FT-2002 and other IDH inhibitors are in different stages of study.
The number of cancer patients in China is huge, according to the National Cancer Center in January 2019 disclosed the national cancer statistics, in China, nearly 4 million new cancer patients each year, an average of more than 10,000 people are diagnosed with cancer every day, 7.5 people per minute.
the number of malignant tumor deaths accounted for 23.91% of all deaths of residents, and for more than 10 years, the incidence of malignant tumors has been increasing by about 3.9% per year, and the mortality rate has been increasing by 2.5% per year.
the current, there is no targeted IIDH inhibitors approved for the market, however, keystone pharmaceutical, sacred and pharmaceutical, and Yellow Medicine, sea and biological pharmaceutical companies are making efforts in this area.
Keystone Pharmaceuticals: ivosidenib process: in the first half of 2020 to submit new drug listing applications, Cornerstone Pharmaceuticals from Agios introduced ivosidenib is currently carrying out a number of registration trials, the company in the release of 2 The innovative drug TIBSovo (ivosidenib) is expected to be approved this year in Taiwan, China, for the treatment of relapsed/refractic acute myeloid leukemia (R/R AML), the company said in its 2019 annual report.
addition, the head of Keystone Pharmaceuticals said that in addition to Taiwan, the first half of 2020 will be planned for the same adaptive disease in Chinese mainland to submit applications for the new drug avapritinib to meet the needs of more patients.
it is worth mentioning that this is also a domestic enterprises in the rapid progress of one.
San and Pharmaceutical Products: SH1573 Capsule Process: A phase 1 clinical study of SH1573 Capsules, a new class of drugs for Sage Pharmaceuticals, was launched in June 2018 for special approval for the treatment of malignant hematomas.
June 2019, the product was successfully conducted in a multi-center Phase 1/2 clinical study in patients with relapsed or incurable AML with IDH2 mutations.
currently, St. He Pharmaceuticals is conducting phase 1 clinical studies of SH1573.
and Yellow Pharmaceutical Products: HMPL-306 Process: Completed first patient drug treatment and Yellow Pharmaceuticals on August 5, 2020 at the same time as the first half of 2020 results release, but also announced key clinical projects and commercial development of new progress.
HMPL-306 is a 1/2 double inhibitor of isochlic acid dehydrogenase (IDH), which is also the 9th innovative cancer drug developed by He Huang Pharmaceuticals.
, IDH1/2 mutations can lead to abnormally high methylation of DNA and histogenes, which can lead to changes in the modification of exogenic genetic abnormalities that affect the transcriptional expression of certain related genes, which in turn can lead to tumor occurrence.
HMPL-306 is expected to address potential IDH mutant transformation, converting IDH1 to IDH2, or the other way.
, the product's Phase 1 clinical trial in China was completed in late July, and the company plans to submit its IND and start Phase 1 clinical trials in the U.S. in the next six months.
sea and biological products: HH2301 process: has been approved by FDA clinical trials isocit acid dehydrogenase-1 (IDH1) inhibitor HH2301 is a new, efficient and specific mIDH1 inhibitor jointly developed by Hai and Biologics and Shanghai Pharmaceuticals.
early May, Haihe Bio announced that its HH2301 had been approved by FDA clinical trials to treat solid tumors with IDH1 mutations, including advanced bile tube cancer, cartilage sarcoma and glioma.
that preclinical studies have shown that HH2301 has excellent in vivo anti-tumor activity and has good pharmacodynamic properties and safety in all test genus.
In addition to the above-mentioned pharmaceutical companies, according to the drug clinical trial registration and information publicity platform, Zhengtianqing 1 class of new drug TQB3455 tablets have been registered in China to carry out 3 phase 1 clinical trials, the variety is mainly for patients with advanced malignant solid tumors or blood tumors, and IDH2 gene mutations of solid tumors and AML.
.